News & Updates

Use of aspirin in the long term appears to markedly reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV), a study has shown.

Administration of oral silymarin leads to a substantial decrease in hepatotoxicity severity after 1 month of treatment in nonmetastatic breast cancer patients on doxorubicin/cyclophosphamide-paclitaxel (AC-T) regimen, reports a study.

Cardiometabolic risk factors increase the risk of nonalcoholic fatty liver disease (NAFLD), though such interactions seem to vary between lean and nonlean individuals, a recent study has found.

In patients with primary biliary cholangitis, the use of seladelpar, a selective peroxisome proliferator-activated receptor-delta agonist, safely improves biochemical markers of cholestasis and inflammation, reports a new study.

Administration rates of antiviral therapy remain low among treatment-eligible patients with chronic hepatitis B virus (CHB) and among CHB patients without human immunodeficiency virus (HIV), reveals a recent study.

The combination of atezolizumab and bevacizumab is better than sorafenib at maintaining clinically meaningful survival benefits over the long term in patients with unresectable hepatocellular carcinoma (HCC), reports a recent update to the IMbrave150 study.

Extracellular vesicles enriched with the polymeric immunoglobulin receptor molecule contributes to tumorigenesis and cancer stemness in patients with hepatocellular carcinoma (HCC), reports a recent study.

A prospective clinical study conducted by the Hong Kong Baptist Hospital in collaboration with the Hong Kong Polytechnic University has demonstrated the feasibility of implementing respiratory-gated PET-CT for liver malignancies with improved image quality compared with ungated scans.